CCORF Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $67

Futu NewsDec 17 22:34 · Ratings

Canaccord Genuity Sticks to Its Buy Rating for Merus (MRUS)

TipRanksDec 17 21:45 · Ratings

Merus Announces First Patient Dosed In The Phase 2 Trial Evaluating Petosemtamab Monotherapy In Heavily Pretreated Metastatic Colorectal Cancer

BenzingaDec 17 05:02

BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $73

Futu NewsDec 11 23:31 · Ratings

BofA Securities Maintains Merus(MRUS.US) With Buy Rating, Announces Target Price $73

Futu NewsDec 11 18:31 · Ratings

Promising Potential of Merus's Petosemtamab in HNSCC: A Buy Recommendation

TipRanksDec 11 18:16 · Ratings